Cumberland Valley Retina Consultants
Cumberland Valley Retina Consultants
Hagerstown, Maryland, United States25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) | eye disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07867080 | |
| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06510816 | |
| A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD | Geographic Atrophy, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-10-05 | NCT06659549 | |
| COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-02 | NCT07449936 | |
| CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-02 | NCT07449923 | |
| A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-10-01 | NCT06962839 | |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-10-01 | NCT06321302 | |
| A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-09-30 | NCT06769048 | |
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06635148 | |
| Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-09-10 | NCT06659445 | |
| An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Not yet recruiting | Phase 3 | 2026-09-08 | NCT07807969 | |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | NCT06683742 | |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | NCT06668064 | |
| 4D-150 in Patients With Diabetic Macular Edema | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic macular edema, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-08-21 | NCT05930561 | |
| 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT05197270 | |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-08-19 | NCT04567550 | |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Enrolling by invitation | Phase 2 | 2026-08-05 | NCT05296447 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-05-18 | NCT06996080 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-05-18 | NCT06990399 | |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Wet Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2026-04-29 | NCT06556368 | |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 3 | 2026-04-16 | NCT07064759 | |
| A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | background diabetic retinopathy | Recruiting | Phase 3 | 2026-03-16 | NCT07235085 | |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-06-17 | NCT06495918 | |
| Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME | diabetic macular edema | Active, not recruiting | Phase 2 | 2025-05-04 | NCT05387837 | |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-04-18 | NCT06223958 |